Search
Clinician Ordering Portal
Scientific evidence
Prediction of neoplastic progression in Barrett’s esophagus by pathologic assessment of degree of crypt atypia and by TissueCypher
May 2020
TissueCypher provided superior risk stratification that outperformed crypt atypia scores.
Publication: Poster presentation (Sa1203) at DDW 2020, Virtual
Independent validation of TissueCypher to predict progression in community- based Barrett's esophagus with low-grade dysplasia: analysis in a completed prospective study
May 2020
TissueCypher may be a practical and effective solution to the lack of standardization of expert pathology review if LGD as advocated by all guidelines.
Publication: Podium presentation (1085) at DDW 2020, virtual
Independent validation of TissueCypher to predict future progression in non- dysplastic Barrett’s esophagus: a spatial-temporal analysis
May 2020
An independent validation study showed TissueCypher identified a significant subset of NDBE patients who progress at a rate comparable to expert-confirmed LGD.
Publication: Poster presentation (Sa1189) at DDW 2020, Virtual
Prediction of neoplastic progression in Barrett’s esophagus by pathologic assessment of degree of crypt atypia and by TissueCypher
May 2020
TissueCypher provided superior risk stratification that outperformed crypt atypia scores.
Publication: Poster presentation (Sa1203) at DDW 2020, Virtual
Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma
Apr 2020
To develop and validate a gene expression profile (GEP) test for predicting risk for metastasis in localized, high-risk cSCC with the goal of improving risk-directed patient management.
Publication: JAAD
Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients
Mar 2020
Meta-analysis stage I-II patients. GEP consistently identifies melanoma patients at increased risk of metastasis, independent of clinicopathologic features and can be used in conjunction with traditional staging to improve patient risk stratification.
Publication: Journal of the American Academy of Dermatology
Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling
Mar 2020
The multicenter Clinical Application of DecisionDx-UM Gene Expression Assay Results study provides prospective validation of the clinical utility of the 15-gene expression profile test in directing metastatic surveillance imaging, follow-up and referral patterns.
Publication: Melanoma Management
Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American Society for Radiation Oncology Clinical practice guideline
Dec 2019
This guideline reviews the evidence for the use of definitive and postoperative radiation therapy (RT) in patients with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC).
Publication: Pract Radiat Oncol
A cost-effectiveness analysis of an adenocarcinoma risk prediction multi-biomarker assay for patients with Barrett’s esophagus
Oct 2019
The TissueCypher assay would be cost-effective after five years and improves patient outcomes by improving effectiveness of surveillance and treatment protocols.
Publication: ClinicoEconomics and Outcomes Research
Evaluation of additional spatial and temporal information increases the overall accuracy of an objective risk prediction assay in patients with non-dysplastic Barrett’s esophagus
Oct 2019
TissueCypher may be a effective solution to aid decision-making on surveillance intervals and therapeutic interventions in the management of NDBE patients.
Publication: Poster presentation (371) at ACG 2019, San Antonio
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (372) at ACG 2019, San Antonio
An automated, quantitative multiplex immunofluorescence assay accurately risk stratifies Barrett’s esophagus patients with a community-based diagnosis of low-grade dysplasia at a rate comparable to expert pathologists
Oct 2019
TissueCypher risk stratified BE patients with a community-based diagnosis of LGD with an accuracy comparable to three renowned expert pathologists.
Publication: Poster presentation (P1990) at UEG 2019, Barcelona